Form 8-K
8-K — Incannex Healthcare Inc.
Accession: 0001213900-26-093244
Filed: 2026-08-25
Period: 2026-08-25
CIK: 0001873875
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — ea0303140-8k_incannex.htm (Primary)
EX-99.1 — PRESS RELEASE DATED AS OF AUGUST 25, 2026 (ea030314001ex99-1.htm)
GRAPHIC (ea030314001_ex99-1img1.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: ea0303140-8k_incannex.htm · Sequence: 1
false
0001873875
0001873875
2026-08-25
2026-08-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date of
earliest event reported): August 25, 2026
Incannex Healthcare
Inc.
(Exact name of registrant
as specified in its charter)
Delaware
001-41106
93-2403210
(State or other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
Rialto South Tower
Level 23, 525 Collins Street
Melbourne, VIC 3008 Australia
Not applicable
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone
Number, including Area Code: +61 409 840 786
(Former Name or
Former Address, if Changed Since Last Report): Not Applicable
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
Trading Symbol
Name of exchange on which registered
Common Stock, $0.0001 par value per share
IXHL
The Nasdaq Stock Market LLC
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On August
25, 2026, Incannex Healthcare Inc. (the “Company”) issued the press release furnished as Exhibit 99.1.
The information
contained in Item 7.01 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated as of August 25, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
1
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Incannex Healthcare Inc.
Date: August 25, 2026
/s/ Joel Latham
Name:
Joel Latham
Title:
Chief Executive Officer and President
2
EX-99.1 — PRESS RELEASE DATED AS OF AUGUST 25, 2026
EX-99.1
Filename: ea030314001ex99-1.htm · Sequence: 2
Exhibit 99.1
Incannex Announces First Patient Dosed in DReAMzz
Phase 2 Study of IHL-42X
First patient dosing represents another major
clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast
Track designation
NEW YORK and MELBOURNE, Australia, August 25, 2026 — Incannex
Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing
innovative combination therapies for high-impact indications, today announced that the first patient has been dosed in the DReAMzz Phase
2 dose-optimization study of IHL-42X, the Company’s oral fixed-dose combination drug candidate for the treatment of obstructive
sleep apnea (“OSA”). The milestone builds on the positive results from the Phase 2 RePOSA study, in which IHL-42X demonstrated
statistically significant reductions in apnea-hypopnea index (“AHI”) compared with placebo, with individual reductions in
AHI of up to 83% observed and exceptional safety profile.
First patient dosing represents another significant milestone in the
continued advancement of IHL-42X and follows a period of substantial clinical and regulatory progress for the program. Over the past year,
Incannex has reported positive Phase 2 RePOSA results, received Fast Track designation from the U.S. Food and Drug Administration (“FDA”),
and advanced its regulatory strategy following engagement with the FDA. The company’s current focus, the DReAMzz dose-optimization
study, recently commenced patient screening and has now progressed to active patient dosing. All 14 DReAMzz sites now have approval from
the Institutional Review Board to conduct the study.
The DReAMzz study is designed to further optimize dose selection for
IHL-42X and strengthen the clinical and regulatory foundation for the Company’s planned Phase 3 development program.
Joel Latham, President and Chief Executive Officer of Incannex,
said:
“Dosing the first patient in DReAMzz is another important milestone
for IHL-42X and continues a period of significant clinical and regulatory progress for the program.
“The momentum behind IHL-42X has continued to build over the
past year. We delivered positive RePOSA results, including statistically significant reductions in AHI and individual reductions of up
to 83%, secured FDA Fast Track designation, advanced our regulatory strategy and have now commenced patient dosing in DReAMzz.
“We believe IHL-42X has the potential to
reshape the treatment landscape for obstructive sleep apnea. OSA affects hundreds of millions of people globally, yet there remains a
significant need for an effective oral pharmaceutical treatment. The clinical results generated to date give us increasing confidence
in the potential of IHL-42X to address that need.
“Our focus now is execution. DReAMzz is designed to optimize
the treatment regimen and provide the data required to advance IHL-42X toward Phase 3 development. With strong clinical data, FDA Fast
Track designation and DReAMzz now actively dosing patients, we believe IHL-42X is exceptionally well positioned as we enter this next
stage of development.”
FDA Fast Track Designation Supports Continued Development
The clinical progress of IHL-42X was further reinforced by the FDA
granting Fast Track designation to the program.
Fast Track designation is designed to facilitate the development and
expedite the review of therapies intended to treat serious conditions and address unmet medical needs. The designation provides opportunities
for more frequent interactions with the FDA during development and, subject to applicable requirements, may provide access to mechanisms
intended to accelerate regulatory review.
The designation was supported by the safety, efficacy and pharmacokinetic
data generated across the IHL-42X clinical development program, including the positive results from the Phase 2 RePOSA study.
Incannex believes Fast Track designation, together with the clinical
evidence generated to date, provides important regulatory support as the Company advances IHL-42X through dose optimization and toward
Phase 3 development.
DReAMzz Phase 2 Dose-Optimization Study
DReAMzz is a Phase 2 crossover dose-optimization study designed to
further characterize the dose-response profile of IHL-42X and inform dose selection for subsequent late-stage clinical development.
The study will evaluate objective sleep-related measures alongside
patient-reported outcomes, providing additional data intended to refine the IHL-42X treatment regimen and strengthen the design of the
Company’s planned Phase 3 program.
Incannex has established a network of 14 clinical trial sites across
the United States to support execution of DReAMzz. Drug product has been manufactured, regulatory and operational preparations have been
completed, clinical sites have commenced patient screening and the first patient has now been dosed.
About IHL-42X
IHL-42X is Incannex’s proprietary oral fixed-dose combination
of dronabinol and acetazolamide being developed for the treatment of obstructive sleep apnea.
The combination is designed to target complementary physiological mechanisms
implicated in OSA through a single oral pharmaceutical therapy.
IHL-42X has received Fast Track designation from the U.S. Food and
Drug Administration.
2
About Incannex Healthcare Inc.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company
developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s
lead programs include IHL-42X for obstructive sleep apnea, IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder.
Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and
creating long-term shareholder value. For more information, please visit www.incannex.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking
statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These
statements include, but are not limited to, statements relating to management’s expectations regarding the development, regulatory
progress and commercialization of the Company’s drug candidates, the potential value of the Company’s drug candidates and
business, and potential shareholder value. When or if used in this communication, the words “may,” “could,” “should,”
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,”
“predict” and similar expressions and their variants, as they relate to the Company, its operations or its management, may
identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current
expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions,
and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond
our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash
on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated,
risks associated with the clinical development of IHL-42X and PSX-001, and other risks described in the section entitled “Risk Factors”
described in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29,
2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can
be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers
are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and
reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking
statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au
3
GRAPHIC
GRAPHIC
Filename: ea030314001_ex99-1img1.jpg · Sequence: 3
Binary file (5979 bytes)
Download ea030314001_ex99-1img1.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover
Aug. 25, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 25, 2026
Entity File Number
001-41106
Entity Registrant Name
Incannex Healthcare
Inc.
Entity Central Index Key
0001873875
Entity Tax Identification Number
93-2403210
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
Rialto South Tower
Entity Address, Address Line Two
Level 23
Entity Address, Address Line Three
525 Collins Street
Entity Address, City or Town
Melbourne, VIC
Entity Address, Country
AU
Entity Address, Postal Zip Code
3008
City Area Code
+61
Local Phone Number
409 840 786
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, $0.0001 par value per share
Trading Symbol
IXHL
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 3 such as an Office Park
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine3
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration